Bosentan

證據等級: L5

預測適應症: 9 個

Bosentan: From Pulmonary Arterial Hypertension to Rheumatoid Arthritis

One-Sentence Summary

Bosentan is a dual endothelin receptor antagonist (ETA/ETB) with established use in pulmonary arterial hypertension (PAH) and the prevention of systemic sclerosis-related digital ulcers internationally, though it is not currently marketed in Canada. The TxGNN model predicts it may be effective for Rheumatoid Arthritis, with 1 indirect clinical trial (targeting the related condition Giant Cell Arteritis) and 16 publications — comprising animal studies, reviews, and one case report — currently supporting this research direction.

Quick Overview

Item	Content
Original Indication	Pulmonary Arterial Hypertension (PAH) (based on international approvals; no Canadian DIN on record)
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	99.80%
Evidence Level	L3
Canada Market Status	Not marketed
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Bosentan is a dual endothelin receptor antagonist that competitively blocks both ETA and ETB receptor subtypes. By blocking these receptors, it inhibits the downstream actions of endothelin-1 (ET-1) — a potent vasoconstrictor, pro-fibrotic, and pro-inflammatory mediator. Its proven efficacy in PAH stems from blocking ET-1-driven pulmonary vascular remodeling; in systemic sclerosis, it targets the same pathway to reduce microvascular injury and prevent digital ulcer formation. This places Bosentan firmly within the ET-1 axis, which is increasingly recognized as relevant across a spectrum of inflammatory diseases.

In rheumatoid arthritis (RA), ET-1 levels are measurably elevated in both the plasma and synovial membrane of patients, where ET-1 promotes local angiogenesis and amplifies the release of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-17. This creates a direct mechanistic rationale: antagonizing ETA and ETB receptors in synovial tissue could dampen synovial inflammation and attenuate cartilage destruction. Notably, TNF-α has been shown to upregulate endothelin system gene expression — forming a bidirectional inflammatory loop that Bosentan is positioned to interrupt.

The strongest preclinical support comes from a murine study (PMID 22249931) in which Bosentan significantly ameliorated collagen-induced arthritis (CIA), the most widely validated animal model for human RA. Additional animal experiments confirm ET-1’s direct role in mediating articular nociception and neutrophil accumulation in arthritic joints. That said, detailed mechanism of action data is not formally available in the current Evidence Pack. No human clinical trial specifically targeting RA has been conducted to date, meaning the mechanistic hypothesis — while scientifically grounded — remains unvalidated in patients.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06957002	Phase 2	Not Yet Recruiting	40	Multicenter RCT comparing Bosentan + glucocorticoids vs. glucocorticoids alone in Giant Cell Arteritis (GCA). GCA is a large-vessel autoimmune vasculitis distinct from RA, but both share inflammatory vascular pathology. Indirectly supports Bosentan’s potential role in autoimmune-driven vascular inflammation; no RA-specific trial exists.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
22249931	2012	Animal RCT	Inflammation Research	Most pivotal study. Bosentan (dual ETA/ETB antagonist) significantly ameliorated collagen-induced arthritis in mice; TNF-α was shown to upregulate endothelin system genes in synovial tissue, establishing the ET-1 → RA inflammatory loop
18515326	2008	Animal Study	Journal of Leukocyte Biology	Endothelins modulate inflammatory neutrophil accumulation, edema, and LTB4/TNF-α/CXCL-1 release in zymosan-induced arthritis; ET-1 confirmed elevated in RA synovial membrane
16766656	2006	Animal Study	PNAS	IL-15 induces mechanical hypernociception via a sequential IFN-γ → endothelin → prostaglandin signaling cascade; dual ET receptor blockade abolished the pain response in this RA-relevant model
19969421	2010	Animal Study	Pain	IL-17 mediates articular hypernociception in antigen-induced arthritis; links the RA cytokine milieu to ET-mediated nociceptive pathways
20054770	2009	Case Report	Kardiologia Polska	An 8.5-year-old girl on Bosentan for Eisenmenger syndrome was subsequently diagnosed with juvenile RA and started on naproxen; incidental co-exposure only, no direct therapeutic signal for RA
19851110	2010	Review	Current Opinion in Rheumatology	Broad review of rheumatic skin disease pathophysiology and emerging therapies; contextual background for drug repurposing across rheumatic conditions
19487226	2009	Review	Rheumatology (Oxford)	Reviews vasculopathy and PAH in systemic lupus, Sjögren’s syndrome, and primary vasculitides; confirms ET-1 pathway centrality across rheumatic disease spectrum
24268012	2014	Review	Rheumatic Diseases Clinics of North America	PAH associated with connective tissue diseases (including RA) carries up to 10–15% first-year mortality; highlights the urgency of targeted ET-1 pathway intervention in rheumatic vascular disease
16218473	2005	Review	Lupus	PAH as complication of CTDs including RA, dermatomyositis, and Sjögren’s syndrome; ET-1 deregulation implicated across all subtypes
18238768	2008	Review	AJHP	Comprehensive review of drug therapy options for systemic sclerosis complications; Bosentan’s established use in a closely related rheumatic disease provides indirect therapeutic precedent

Canada Market Information

Bosentan is currently not marketed in Canada per the available regulatory data. No Drug Identification Numbers (DINs) are on record for this jurisdiction.

Note: Bosentan (Tracleer®) holds regulatory approval in other major jurisdictions — including the United States (FDA), European Union (EMA), and Japan (PMDA) — for pulmonary arterial hypertension and prevention of digital ulcers in systemic sclerosis. Canadian market availability should be verified directly with Health Canada’s Drug Product Database prior to any access or trial planning.

Safety Considerations

No formal safety data (warnings, contraindications, or drug interaction records) is available in the current Evidence Pack.

Please refer to the package insert for safety information.

Class-level considerations for endothelin receptor antagonists (for reference from published literature): Bosentan carries known hepatotoxicity risk requiring regular liver function monitoring; it is teratogenic and absolutely contraindicated in pregnancy; it interacts with major CYP3A4 and CYP2C9 substrates (including warfarin, ciclosporin, and oral contraceptives). In the RA population — who commonly receive DMARDs, JAK inhibitors, or biologics — formal pharmacokinetic drug interaction assessment will be essential before any clinical use. These points must be confirmed via the official product monograph.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic case for Bosentan in RA is scientifically credible — ET-1 is elevated in RA synovial tissue, animal models of collagen-induced arthritis demonstrate clear therapeutic benefit, and the drug’s established anti-inflammatory and anti-vascular-remodeling activity in closely related conditions (PAH, systemic sclerosis) provides pharmacological precedent. However, the evidence base remains entirely preclinical and observational; no human clinical trial directly addressing RA has been initiated, and the one registered trial (NCT06957002) targets a different autoimmune vasculitis (GCA). The current evidence level (L3) does not meet the threshold for direct advancement to clinical application.

To proceed, the following is needed:

A dedicated Phase 1/2 proof-of-concept clinical trial evaluating Bosentan in patients with active RA, including dose-finding and safety assessment
Biomarker studies measuring synovial ET-1 levels in RA patients to confirm target engagement and patient selection criteria
Full MOA documentation from DrugBank and the official product monograph to complete the mechanistic dossier
Formal pharmacokinetic drug interaction profiling in the RA patient population (typical co-medications: methotrexate, biologics, JAK inhibitors)
Health Canada regulatory consultation regarding feasibility of an investigational trial given the current non-marketed status in Canada
TFDA prescribing information (package insert) retrieval to resolve the current safety data gap (DG001)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.